Unique exon 1 sequences in cohort 1
| Deduced leader peptide . | Nucleotide sequence for nonamer peptide . | Total (% of total cohort) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| P1 . | P2 . | P3 . | P4 . | P5 . | P6 . | P7 . | P8 . | P9 . | ||
| VMAPRTVLL* | GTC | ATG | GCG | CCC | CGA | ACC | GTC | CTC | CTG | 683 153 (31.1) |
| VTAPRTVLL† | — | -C- | — | — | — | — | — | — | — | 670 904 (30.5) |
| VTAPRTLLL‡ | — | -C- | — | — | — | — | C- | — | — | 542 311 (24.7) |
| VTAPRTVLL† | — | -C- | -A | — | — | — | — | — | — | 242 366 (11.0) |
| VTAPRTLLL‡ | — | -C- | -A | — | — | — | C- | — | — | 57 747 (2.6) |
| VTEPRTLLL | — | -C- | -A- | — | — | — | C- | — | — | 107 |
| VMAPRTVLL* | — | — | — | — | A- | — | — | — | — | 25 |
| VMAPRTVLL* | — | — | -A | — | — | — | — | — | — | 21 |
| VTAPRTVLL† | — | -CC | — | — | — | — | — | — | — | 16 |
| VTAPRTLLL‡ | — | -C- | -T | — | — | — | C- | — | — | 10 |
| VTAPRTLFL | — | -C- | -A | — | — | — | C- | T- | — | 7 |
| VTASRTLLL | — | -C- | — | T- | — | — | C- | — | — | 6 |
| VMAPRTLLL | — | — | — | — | — | — | C- | — | — | 5 |
| VTASRTVLL | — | -C- | — | T- | — | — | — | — | — | 4 |
| VRAPRTLLL | — | -G- | -A | — | — | — | C- | — | — | 3 |
| VTAPRTILL | — | -C- | — | — | — | — | A- | — | — | 3 |
| VTAPRNLLL | — | -C- | — | — | — | -A- | C-– | — | — | 3 |
| VMAPRTVLL* | — | — | — | — | — | — | — | — | T- | 3 |
| VTAPRTVLL† | — | -C- | -A | — | — | — | — | — | -A | 3 |
| VTAPQTVLL | — | -C- | — | — | -A- | — | — | — | — | 3 |
| VTATRTLLL | — | -C- | — | A- | — | — | C- | — | — | 2 |
| VTALRTVLL | — | -C- | — | -T- | — | — | — | — | — | 1 |
| VTAPRTLVL | — | -C- | — | — | — | — | C- | G- | — | 1 |
| ITAPRTVLL | A- | -C- | — | — | — | — | — | — | — | 1 |
| VMEPRTVLL | — | — | -A- | — | — | — | — | — | — | 1 |
| VTAP*TLLL | — | -C- | — | — | T- | — | C- | — | — | 1 |
| VTAPRTLLL‡ | — | -C- | — | — | — | — | C- | — | -A | 1 |
| VTAPRTFLL | — | -C- | — | — | — | — | T– | — | — | 1 |
| VMATRTVLL | — | — | — | A- | — | — | — | — | — | 1 |
| VMAPGTVLL | — | — | — | — | G- | — | — | — | — | 1 |
| VTAPRTVLQ | — | -C- | — | — | — | — | — | — | -A- | 1 |
| VMAPRSVLL | — | — | — | — | — | -G- | — | — | — | 1 |
| VVAPRTVLL | — | G- | — | — | — | — | — | — | — | 1 |
| VMVPRTVLL | — | — | -T- | — | — | — | — | — | — | 1 |
| VMAPRTVLV | — | — | — | — | — | — | — | — | G- | 1 |
| Total | 2 196 716 | |||||||||
| Deduced leader peptide . | Nucleotide sequence for nonamer peptide . | Total (% of total cohort) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| P1 . | P2 . | P3 . | P4 . | P5 . | P6 . | P7 . | P8 . | P9 . | ||
| VMAPRTVLL* | GTC | ATG | GCG | CCC | CGA | ACC | GTC | CTC | CTG | 683 153 (31.1) |
| VTAPRTVLL† | — | -C- | — | — | — | — | — | — | — | 670 904 (30.5) |
| VTAPRTLLL‡ | — | -C- | — | — | — | — | C- | — | — | 542 311 (24.7) |
| VTAPRTVLL† | — | -C- | -A | — | — | — | — | — | — | 242 366 (11.0) |
| VTAPRTLLL‡ | — | -C- | -A | — | — | — | C- | — | — | 57 747 (2.6) |
| VTEPRTLLL | — | -C- | -A- | — | — | — | C- | — | — | 107 |
| VMAPRTVLL* | — | — | — | — | A- | — | — | — | — | 25 |
| VMAPRTVLL* | — | — | -A | — | — | — | — | — | — | 21 |
| VTAPRTVLL† | — | -CC | — | — | — | — | — | — | — | 16 |
| VTAPRTLLL‡ | — | -C- | -T | — | — | — | C- | — | — | 10 |
| VTAPRTLFL | — | -C- | -A | — | — | — | C- | T- | — | 7 |
| VTASRTLLL | — | -C- | — | T- | — | — | C- | — | — | 6 |
| VMAPRTLLL | — | — | — | — | — | — | C- | — | — | 5 |
| VTASRTVLL | — | -C- | — | T- | — | — | — | — | — | 4 |
| VRAPRTLLL | — | -G- | -A | — | — | — | C- | — | — | 3 |
| VTAPRTILL | — | -C- | — | — | — | — | A- | — | — | 3 |
| VTAPRNLLL | — | -C- | — | — | — | -A- | C-– | — | — | 3 |
| VMAPRTVLL* | — | — | — | — | — | — | — | — | T- | 3 |
| VTAPRTVLL† | — | -C- | -A | — | — | — | — | — | -A | 3 |
| VTAPQTVLL | — | -C- | — | — | -A- | — | — | — | — | 3 |
| VTATRTLLL | — | -C- | — | A- | — | — | C- | — | — | 2 |
| VTALRTVLL | — | -C- | — | -T- | — | — | — | — | — | 1 |
| VTAPRTLVL | — | -C- | — | — | — | — | C- | G- | — | 1 |
| ITAPRTVLL | A- | -C- | — | — | — | — | — | — | — | 1 |
| VMEPRTVLL | — | — | -A- | — | — | — | — | — | — | 1 |
| VTAP*TLLL | — | -C- | — | — | T- | — | C- | — | — | 1 |
| VTAPRTLLL‡ | — | -C- | — | — | — | — | C- | — | -A | 1 |
| VTAPRTFLL | — | -C- | — | — | — | — | T– | — | — | 1 |
| VMATRTVLL | — | — | — | A- | — | — | — | — | — | 1 |
| VMAPGTVLL | — | — | — | — | G- | — | — | — | — | 1 |
| VTAPRTVLQ | — | -C- | — | — | — | — | — | — | -A- | 1 |
| VMAPRSVLL | — | — | — | — | — | -G- | — | — | — | 1 |
| VVAPRTVLL | — | G- | — | — | — | — | — | — | — | 1 |
| VMVPRTVLL | — | — | -T- | — | — | — | — | — | — | 1 |
| VMAPRTVLV | — | — | — | — | — | — | — | — | G- | 1 |
| Total | 2 196 716 | |||||||||
The 1 098 358 donors in cohort 1 contain 2 196 716 observed exon 1 nucleotide sequences (each of which encodes a deduced peptide sequence). Each row details a unique nucleotide sequence. Nucleotide sequence rows are sorted by decreasing observations. Nucleotide sequences are aligned with the most frequent sequence; hyphens indicate consensus nucleotides. The asterisk within VTAP*TLLL indicates a deduced stop codon. The P2 sequence is indicated in bold, which is deduced to encode thymine (T) (1 513 499 observations); methionine (M) (683 213 observations); arginine (R) (three observations), or valine (V) (one observation). Percentages are provided for the top 5 peptides, which represent 99.99% of all observations. Race information for each peptide is provided in Table 4. Deduced leader peptides with multiple unique nucleotide sequences are annotated with footnotes.
These deduced leader peptides have 4 unique exon 1 sequences each in cohort 1.